Published on 6 Mar 2024 on Simply Wall St. via Yahoo Finance
Analysts Have Made A Financial Statement On Cara Therapeutics, Inc.'s (NASDAQ:CARA) Yearly Report
As you might know, Cara Therapeutics, Inc. (NASDAQ:CARA) last week released its latest full-year, and things did not turn out so great for shareholders. Earnings missed the mark badly, with revenues of US$21m falling 24% short of expectations. Losses correspondingly increased, with a US$2.19 per-share statutory loss some 12% larger than what the analysts expected. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.
View our latest analysis for Cara Therapeutics
